We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Rising Hope for Oral Peanut Allergy Treatment

By HospiMedica International staff writers
Posted on 24 Jan 2013
Sublingual immunotherapy (SLIT) appears to desensitize therapy peanut allergy, with better results the longer therapy continues, according to a new study.

Researchers at National Jewish Health (Denver, CO, USA) conducted a randomized trial to investigate safety, efficacy, and immunologic effects of peanut SLIT. More...
Following a baseline oral food challenge (OFC) of up to 2 grams of peanut powder, 40 subjects—aged 12 to 37 years—were randomized to daily peanut or placebo SLIT. A five gram OFC was performed after 44 weeks, followed by unblinding. Placebo-treated subjects then crossed over to higher dose peanut SLIT protocol. Both groups were then compared with baseline OFCs, with subjects with a successfully consumed dose (SCD) of 5 grams or at least 10-fold more peanut powder than the baseline OFC threshold considered as responders.

The results showed that after 44 weeks of SLIT, 70% of the subjects receiving peanut SLIT were responders, compared with 15% in those receiving placebo. In peanut SLIT responders, median SCD increased from 3.5 to 496 mg. After 68 weeks of SLIT, median SCD significantly increased to 996 mg. The median SCD at the Week 44 Crossover OFC was also significantly higher than baseline, with 44% of the 16 crossover subjects being responders, with median SCD increasing from 21 to 496 mg. The study was published in the January 2013 issue of the Journal of Allergy and Clinical Immunology.

“These data suggest continued long-term therapy with peanut SLIT might confer reduced reactivity to peanut after further desensitization, allowing for protection against accidental ingestions, which are reactions to less than 100 mg of peanut protein in general,” concluded lead author David Fleischer, MD, and colleagues. “While encouraging, the effect of sublingual immunotherapy at 44 weeks appeared to be modest desensitization that didn't reach the threshold of five grams without symptoms, which might not provide clinically relevant protection.”

Peanut allergy is a type 1 hypersensitivity reaction to dietary substances from peanuts that causes an overreaction of the immune system, which in a small percentage of people may lead to severe physical symptoms; it is estimated to affect 0.4%–0.6% of the population. The most severe allergies in general can result in anaphylaxis, an emergency requiring immediate attention and treatment with epinephrine. Peanut allergies are usually treated with an exclusion diet and vigilant avoidance of foods that may contain whole peanuts or peanut particles and/or oils.

Related Links:
National Jewish Health




Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Digital Color Doppler Ultrasound System
MS22Plus
Endoscopy Display
E190
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The AI-based approach identifies lipid regions matched well with histopathology results (Photo courtesy of Hyeong Soo Nam/KAIST)

AI-Based OCT Image Analysis Identifies High-Risk Plaques in Coronary Arteries

Lipid-rich plaques inside coronary arteries are strongly associated with heart attacks and other major cardiac events. While optical coherence tomography (OCT) provides detailed images of vessel structure... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.